On the 27th of January 2012, the Ifakara Health Institute has started recruitment in the PanACEA HIGHRIF tuberculosis trial at the Bagamoyo Research and Training Centre. The PanACEA HIGHRIF study is a phase II clinical trial in Tanzanian tuberculosis patients on the pharmacokinetics, safety/tolerability and efficacy of higher than standard doses rifampicin (900 and 1200 mg versus standard 600 mg). This trial (Site PI: Dr. Klaus Reither) investigates the potential of higher dosages of rifampicin to shorten and simplify the treatment of tuberculosis. The HIGHRIF project is one of the three major components of the overarching plan of the PanACEA Consortium, funded by European and Developing Countries Clinical Trials Partnership (EDCTP). The overall aim of the PanACEA Consortium is to advance the development of TB therapeutics, to establish TB clinical trial capacities in Sub-Saharan Africa and to establish new tools for future TB clinical trials. |
|
Announcements >
Could high-dose rifampicin shorten TB treatment?posted 27 Jan 2012 05:20 by IHI Webmaster |
© IFAKARA Health Institute (IHI), 2011 Site Visitors